Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Veliparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 6/20 | 1.00 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 0.98 |
| ▸ | TNKS | O95271 | 1/20 | 0.98 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.98 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.98 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.98 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.98 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veliparib SCHEMBL2368887 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29455770 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368883 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422320 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422319 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29354914 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL5511373 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422318 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL30418660 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29843298 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273170-B2 | Methods of treating cancer | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2022-03-15 | — | — | US | disclosed |
| US-20190269711-A1 | METHODS OF TREATING CANCER | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2019-09-05 | — | — | US | disclosed |
| EP-3487999-A1 | METHODS OF TREATING CANCER | Ascend Biopharmaceuticals Ltd (AU) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018018073-A1 | METHODS OF TREATING CANCER | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2018-02-01 | — | — | WO | disclosed |
| US-9580410-B2 | 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1 | ABBVIE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2722046-B1 | 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1 | ABBVIE IRELAND UNLIMITED CO (IE) | 2016-12-21 | — | — | EP | disclosed |
| US-20150148392-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | ABBVIE INC. | 2015-05-28 | — | — | US | disclosed |
| EP-2727921-A1 | 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 2 | AbbVie Bahamas Limited (BS) | 2014-05-07 | — | — | EP | disclosed |
| EP-2722046-A1 | 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 1 | AbbVie Bahamas Ltd. (BS) | 2014-04-23 | — | — | EP | disclosed |
| US-20130123317-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | ABBVIE INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8372987-B2 | Title compound is Veliparib, a Poly(ADP-ribose) polymerase i.e. PARP inhibitor; anticancer agent | ABBVIE INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8013168-B2 | Veliparib crystal structure; an anticancer PARP inhibitor | ABBOTT LABORATORIES (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2217603-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | Abbott Laboratories (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2212327-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | Abbott Laboratories (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20090099245-A1 | 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099246-A1 | 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009049111-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049109-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099245-A1 | 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | TPMT, MALT1, GOT2 | PARP1 739/4885PARP2 266/4885PARP3 1454/4885 |
| US-20150148392-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | TPMT, UACA, GOT2 | PARP1 757/4885PARP2 260/4885PARP3 1419/4885 |
| US-20130123317-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | TPMT, UACA, GOT2 | PARP1 757/4885PARP2 260/4885PARP3 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.